Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance.

Swastika Maity Karkala Sreedhara Ranganath Pai Yogendra Nayak

Published in: Pharmacological reports : PR (2020)

Composition of this review highlights the advantage of inhibiting allosteric site in the EGFRTK receptor domains and presents a comparative analysis of the new fourth-generation anti-NSCLC agents to overcome the drug resistance.

Keyphrases

small cell lung cancer
small molecule
advanced non small cell lung cancer
epidermal growth factor receptor
brain metastases
signaling pathway
tyrosine kinase
cancer therapy
stem cells
bone marrow
drug delivery